The role of soluble fiber intake in patients under highly effective lipid-lowering therapy

Nutrition Journal

Maria C Izar²  Fernanda C Silva¹  Vinicius M Rezende¹  Ronilson A Moreno¹  Ney C Borges¹  Tatiana Helfenstein²  Flávio T Moreira²  Soraia H Kasmas²  Francisco A Fonseca²  Silvia C Ramos² 

[1] Synchrophar, Praça Vinte e Oito de Fevereiro, 55, Paulínia, 13140-000, SP, Brazil;Department of Medicine, Cardiology Division, Federal University of Sao Paulo, Rua Pedro de Toledo, 276, São Paulo, SP, 04039-030, Brazil

关键词: lipid-lowering therapy;    desmosterol;    campesterol;    lipids;    Soluble fiber;   

Others  :  840112
DOI  :  10.1186/1475-2891-10-80

 received in 2011-01-08, accepted in 2011-08-02,  发布年份 2011

【 摘 要 】

Background

It has been demonstrated that statins can increase intestinal sterol absorption. Augments in phytosterolemia seems related to cardiovascular disease.

Objective

We examined the role of soluble fiber intake in endogenous cholesterol synthesis and in sterol absorption among subjects under highly effective lipid-lowering therapy.

Design

In an open label, randomized, parallel-design study with blinded endpoints, subjects with primary hypercholesterolemia (n = 116) were assigned to receive during 12 weeks, a daily dose of 25 g of fiber (corresponding to 6 g of soluble fibers) plus rosuvastatin 40 mg (n = 28), rosuvastatin 40 mg alone (n = 30), sinvastatin 40 mg plus ezetimibe 10 mg plus 25 g of fiber (n = 28), or sinvastatin 40 mg plus ezetimibe 10 mg (n = 30) alone.

Results

The four assigned therapies produced similar changes in total cholesterol, LDL-cholesterol, and triglycerides (p < 0.001 vs. baseline) and did not change HDL-cholesterol. Fiber intake decreased plasma campesterol (p < 0.001 vs. baseline), particularly among those patients receiving ezetimibe (p < 0.05 vs. other groups), and β-sitosterol (p = 0.03 vs. baseline), with a trend for lower levels in the group receiving fiber plus ezetimibe (p = 0.07). Treatment with rosuvastatin alone or combined with soluble fiber was associated with decreased levels of desmosterol (p = 0.003 vs. other groups). Compared to non-fiber supplemented individuals, those treated with fibers had weight loss (p = 0.04), reduced body mass index (p = 0.002) and blood glucose (p = 0.047).

Conclusion

Among subjects treated with highly effective lipid-lowering therapy, the intake of 25 g of fibers added favorable effects, mainly by reducing phytosterolemia. Additional benefits include improvement in blood glucose and anthropometric parameters.

【 授权许可】

   
2011 Ramos et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report Circulation 2002, 106(25):3143-421.
• [2]Ortega RM, Palencia A, Lopez-Sobaler AM: Improvement of cholesterol levels and reduction of cardiovascular risk via the consumption of phytosterols. Br J Nutr 2006, 96(Suppl 1):S89-93.
• [3]Theuwissen E, Mensink RP: Water-soluble dietary fibers and cardiovascular disease. Physiol Behav 2008, 94(2):285-92.
• [4]Assmann G, Cullen P, Erbey J, Ramey DR, Kannenberg F, Schulte H: Plasma sitosterol elevations are associated with an increased incidence of coronary events in men: results of a nested case-control analysis of the Prospective Cardiovascular Munster (PROCAM) study. Nutr Metab Cardiovasc Dis 2006, 16(1):13-21.
• [5]Patel MD, Thompson PD: Phytosterols and vascular disease. Atherosclerosis 2006, 186(1):12-9.
• [6]Ma Y, Griffith JA, Chasan-Taber L, Olendzki BC, Jackson E, Stanek EJ, Li W, Pagoto SL, Hafner AR, Ockene IS: Association between dietary fiber and serum C-reactive protein. Am J Clin Nutr 2006, 83(4):760-6.
• [7]Asztalos BF, Le Maulf F, Dallal GE, Stein E, Jones PH, Horvath KV, McTaggart F, Schaefer EJ: Comparison of the effects of high doses of rosuvastatin versus atorvastatin on the subpopulations of high-density lipoproteins. Am J Cardiol 2007, 99(5):681-5.
• [8]van Himbergen TM, Matthan NR, Resteghini NA, Otokozawa S, Ai M, Stein EA, Jones PH, Schaefer EJ: Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers. J Lipid Res 2009, 50(4):730-9.
• [9]Catapano AL, Davidson MH, Ballantyne CM, Brady WE, Gazzara RA, Tomassini JE, Tershakovec AM: Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Curr Med Res Opin 2006, 22(10):2041-53.
• [10]Grodos D, Tonglet R: Scandinavian simvastatin study (4S). Lancet 1994, 344(8939-8940):1768.
• [11]Miettinen TA, Gylling H, Lindbohm N, Miettinen TE, Rajaratnam RA, Relas H: Serum noncholesterol sterols during inhibition of cholesterol synthesis by statins. J Lab Clin Med 2003, 141(2):131-7.
• [12]Plat J, Bragt MC, Mensink RP: Common sequence variations in ABCG8 are related to plant sterol metabolism in healthy volunteers. J Lipid Res 2005, 46(1):68-75.
• [13]Davis HR, Veltri EP: Zetia: inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia. J Atheroscler Thromb 2007, 14(3):99-108.
• [14]Miettinen TA, Gylling H, Lindbohm N, Miettinen TE, Rajaratnam RA, Relas H, Finnish Treat-to-Target Study Investigators: Serum noncholesterol sterols during inhibition of cholesterol synthesis by statins. J Lab Clin Med 2003, 141(2):131-7.
• [15]Miettinen TA, Gylling H: Cholesterol synthesis and absorption in coronary patients with lipid triad and isolated high LDL cholesterol in a 4S subgroup. Atherosclerosis 2003, 168(2):343-9.
• [16]Assmann G, Kannenberg F, Ramey DR, Musliner TA, Gutkin SW, Veltri EP: Effects of ezetimibe, simvastatin, atorvastatin, and ezetimibe-statin therapies on non-cholesterol sterols in patients with primary hypercholesterolemia. Curr Med Res Opin 2008, 24(1):249-59.
• [17]Matthan NR, Pencina M, LaRocque JM, Jacques PF, D'Agostino RB, Schaefer EJ, Lichtenstein AH: Alterations in cholesterol absorption/synthesis markers characterize Framingham offspring study participants with CHD. J Lipid Res 2009, 50(9):927-35.
• [18]Bingham SA, Gill C, Welch A, Day K, Cassidy A, Khaw KT, Sneyd MJ, Key TJ, Roe L, Day NE: Comparison of dietary assessment methods in nutritional epidemiology: weighed records v. 24 h recalls, food-frequency questionnaires and estimated-diet records. Br J Nutr 1994, 72(4):619-43.
• [19]Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18(6):499-502.
• [20]Marlett JA, McBurney MI, Slavin JL: Position of the American Dietetic Association: health implications of dietary fiber. J Am Diet Assoc 2002, 102(7):993-1000.
• [21]Brown L, Rosner B, Willett WW, Sacks FM: Cholesterol-lowering effects of dietary fiber: a meta-analysis. Am J Clin Nutr 1999, 69(1):30-42.
• [22]Anderson JW, Baird P, Davis RH Jr, Ferreri S, Knudtson M, Koraym A, Waters V, Williams CL: Health benefits of dietary fiber. Nutr Rev 2009, 67(4):188-205.
• [23]Anderson JW: Dietary fiber, lipids and atherosclerosis. Am J Cardiol 1987, 60(12):17G-22G.
• [24]Gylling H, Puska P, Vartiainen E, Miettinen TA: Serum sterols during stanol ester feeding in a mildly hypercholesterolemic population. J Lipid Res 1999, 40(4):593-600.
• [25]Ketomaki A, Gylling H, Miettinen TA: Effects of plant stanol and sterol esters on serum phytosterols in a family with familial hypercholesterolemia including a homozygous subject. J Lab Clin Med 2004, 143(4):255-62.
• [26]Miettinen TA, Gylling H: The effects of statins and sitosterols: benefit or not? Curr Atheroscler Rep 2009, 11(1):23-7.
• [27]Davis HR Jr, Altmann SW: Niemann-Pick C1 Like 1 (NPC1L1) an intestinal sterol transporter. Biochim Biophys Acta 2009, 1791(7):679-83.
• [28]Salas-Salvado J, Farres X, Luque X, Narejos S, Borrell M, Basora J, Anguera A, Torres F, Bulló M, Balanza R, Fiber in Obesity-Study Group: Effect of two doses of a mixture of soluble fibres on body weight and metabolic variables in overweight or obese patients: a randomised trial. Br J Nutr 2008, 99(6):1380-7.
• [29]Tucker LA, Thomas KS: Increasing total fiber intake reduces risk of weight and fat gains in women. J Nutr 2009, 139(3):576-81.
• [30]Vuksan V, Rogovik AL, Jovanovski E, Jenkins AL: Fiber facts: benefits and recommendations for individuals with type 2 diabetes. Curr Diab Rep 2009, 9(5):405-11.
• [31]Panahi S, Ezatagha A, Temelli F, Vasanthan T, Vuksan V: Beta-glucan from two sources of oat concentrates affect postprandial glycemia in relation to the level of viscosity. J Am Coll Nutr 2007, 26(6):639-44.
• [32]Mello VD, Laaksonen DE: Dietary fibers: current trends and health benefits in the metabolic syndrome and type 2 diabetes. Arq Bras Endocrinol Metabol 2009, 53(5):509-18.
• [33]Kim H, Stote KS, Behall KM, Spears K, Vinyard B, Conway JM: Glucose and insulin responses to whole grain breakfasts varying in soluble fiber, beta-glucan: a dose response study in obese women with increased risk for insulin resistance. Eur J Nutr 2009, 48(3):170-5.
• [34]Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM: Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care 2009, 32(10):1924-9.
• [35]Sattar N, Preiss D, Murray HM, Paul Welsh, Brendan BuckleyM, Anton de CraenJM, Sreenivasa Rao Kondapally Seshasai, John McMurrayJ, Dilys FreemanJ, Wouter JukemaJ, Peter MacfarlaneW, Chris PackardJ, David StottJ, Rudi WestendorpG, James Shepherd, Barry DavisR, Sara PresselL, Roberto Marchioli, Rosa Maria Marfisi, Aldo MaggioniP, Luigi Tavazzi, Gianni Tognoni, John Kjekshus, et al.: Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010, 375(9716):735-42.
• [36]Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R: Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376(9753):1670-81.